H.I.G. BioVentures

H.I.G. BioVentures
July 29, 2011
H.I.G. Capital – Corporate Overview
H.I.G. is one of the leading private equity firms in the small-cap segment of the market
Founded in 1993; over $9 Billion under management
More than 200 investment professionals
• North America: Miami, Atlanta, Boston, San Francisco, New York, Maryland
• Europe: London, Paris, Hamburg
H.I.G. Funds:
• Venture/Growth Investments: H.I.G. BioVentures; H.I.G. Growth Partners
• Buyout Investments: U.S. LBO, Europe LBO
• Distressed Investments: Bayside Capital (debt)
• Public Equities: Brightpoint Capital
“Institutionalized” management structure/processes with strong financial staff/controls,
legal/compliance, IT support, and risk management procedures in place
Differentiated, value-added strategy has resulted in superior track record
H.I.G. BioVentures – Background
Established dedicated life science focus in 2004 :
Approximately $350 Million in capital under management
$150 Million committed to existing portfolio companies
Currently investing out of H.I.G. BioVentures II
Experienced team focused exclusively on life science investing
Sectors: biopharmaceuticals, medical devices, diagnostics
H.I.G. BioVentures is the lead or co-lead investor in all investments
• Active board representation in all companies
H.I.G. BioVentures – Team
Four senior investment professionals with collectively more than 30 years of
venture capital investing experience
The H.I.G. BioVentures team has complementary backgrounds covering
• Research and intellectual property
• Product and process development
• Business development
• Operations
• Finance
• Sales and marketing
The H.I.G. BioVentures team also has a deep network of advisors, coinvestors, corporate leaders, and technical consultants to leverage during due
diligence and on behalf of portfolio companies
H.I.G. BioVentures – Industry Leadership
The H.I.G. BioVentures team is active with numerous academic and non-profit
Boards of regional venture capital organizations:
o Mid-Atlantic Venture Association (MAVA), FL Bio, GA Bio
Board and committee participation at national and regional conferences:
o Bio-Investor Forum, Mid-Atlantic Bio, Southeast Bio Investor Forum, FL Venture Forum,
Midwest Healthcare Investor Network
Board/advisory member for universities and entrepreneurial organizations :
o Johns Hopkins Alliance, Maryland Technology Enterprise Institute, North Texas
Enterprise Corporation, Texas Bioscience Council, Coulter Foundation (Emory, Ga.
Tech), Sid Martin Biotechnology Incubator , Univ. Miami, Univ. Florida, Univ. Delaware
Research Foundation, Virginia CIT Gap Fund Investment Board (affiliated with all
Virginia Universities), Enterprise Florida
Not-for-profit boards :
o Adventist Healthcare
Speaker/panelist :
o Multiple national and regional conferences including BIO 2011
H.I.G. BioVentures – Aaron Davidson
Executive management at Eli Lilly and Company
• Business development
• Sales and marketing
• Finance
• General management
Venture capital experience at Ventures West
• Leading Canadian healthcare investor
Operating history at Eli Lilly and Company and venture-backed SYN-X
Broad network in the pharmaceutical and biotechnology industry as well
within the venture capital community.
M.B.A., Harvard Business School
B.Comm., McGill University
(305) 379-2322
H.I.G. BioVentures – Bruce Robertson
Operating experience in both business development
and R&D
• IGEN (acquired by Roche)
• W.R. Grace
Venture capital experience at Toucan Capital and
GIV Venture Partners
Extensive relationships in the Mid-Atlantic’s financial, entrepreneurial and
scientific/academic community
Well-connected within broad venture capital community
M.B.A., Harvard Business School
Ph.D., University of Delaware (Biomedical Engineering)
B.S.E., University of Pennsylvania
(305) 379-2322
H.I.G. BioVentures – Michael Wasserman
Operating experience in entrepreneurial/venturebacked biotechnology
• Founder and VP, Business Development at
CELLutions Biosystems (acq. by Cedarlane Labs)
Background in early-stage technology transfer and development as
a Principal with Innovations Foundation
Clinical drug development and regulatory expertise based on tenure
at Advanced Therapeutics
Extensive network and deal flow resources in multiple geographies – Southeast,
Midwest, Texas, Ohio, etc.
Ph.D., University of Toronto (Pharmacology)
B.S., McGill University
(305) 379-2322
H.I.G. BioVentures – Michael Gutch
Venture Capital experience at Lilly Ventures,
Eli Lilly and Company
Member of the Corporate Finance & Investment
Banking group at Eli Lilly and Company
Post-doctoral research experience at Cold Spring Harbor Labs and UCSF
Strong associations in the pharmaceutical and entrepreneurial communities and
networked throughout the Midwest and Northwest
M.B.A., Indiana University
Ph.D., State University of New York (Molecular & Cellular Pathology)
B.S., Alfred University
(305) 379-2322
H.I.G. BioVentures – Investment Strategy
Areas of Unmet
Medical Need
• Large, attractive markets
• Significant unmet medical
• Chronic or acute care high
value per patient disease
Validation &
Efficient Clinical
• Clear and meaningful clinical
• Short clinical development
timelines to demonstrate proofof-concept in appropriate
patient groups
• Scientific and clinical
validation well established
• Differentiation from current
standard of care
• Regulatory precedent
Broad Source of
Deal Flow
• Extensive networks outside of
CA and MA resulting in
proprietary deal flow
• Approximately 80% of
investments in “secondary
H.I.G. BioVentures – Partnering with Industry
H.I.G. BioVentures values its long-term relationships with the pharma and
medical device industries
H.I.G. BioVentures has:
• Co-invested with corporate venture capital groups such as MedImmune
Ventures, SROne, Novo A/S
• Strong relationships with most pharmaceutical and med-tech corporate
venture capital and business development groups
• Ongoing discussions with CVC and BD groups on existing portfolio
companies and new deal opportunities
H.I.G. BioVentures portfolio companies have recently completed transactions
H.I.G. BioVentures – Summary
Dedicated to investing in high potential life sciences companies
Team of experienced investment professionals with deep domain knowledge
Proprietary deal flow developed through a broad relationship network
Ability to leverage the more than 200 investment professionals across the
H.I.G. Capital platform
Building business relationships with pharmaceutical, biotechnology, and
medical device companies

similar documents